Financial Data and Key Metrics Changes - Revenue for the full year 2025 reached approximately $120 million, reflecting a 10% year-over-year growth driven by improvements in average selling price and volumes [51][58] - Adjusted EBITDA for 2025 was $13.2 million, representing a 26% improvement compared to 2024, despite the impact of GAC startup costs [51][52] - Q4 2025 revenue totaled $29.4 million, up around 8% year-over-year, with a gross margin of 13.6%, significantly impacted by GAC ramp-up costs [54][55] Business Line Data and Key Metrics Changes - The PAC business delivered exceptional performance in 2025, with revenues reaching approximately $120 million, up 10% year-over-year, and adjusted EBITDA of $13 million [38][51] - The company is pausing GAC production to conduct a comprehensive engineering and production process optimization review, with no GAC production expected in 2026 [9][25] Market Data and Key Metrics Changes - The GAC market fundamentals remain strong, with persistent supply shortages against steady annual growth from existing demand drivers [27][28] - The company anticipates that the PAC business will continue to be cash generative in fiscal year 2026 and beyond, with strong visibility into future demand [56][58] Company Strategy and Development Direction - The company is focused on optimizing its GAC production process and has made strategic changes to its leadership team to enhance operational efficiency [32][36] - The shift towards specialty products and engineered materials is expected to improve the business profile and command premium pricing [43][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term demand for GAC, citing a significant demand-supply imbalance that is expected to persist [70][108] - The company is committed to making disciplined capital allocation decisions and is focused on rebuilding investor confidence through consistent execution [62][64] Other Important Information - The company is taking a $45 million write-down on its Corbin assets as part of its decision to switch GAC feedstock to purchased bituminous coal [29][30] - The company ended the year with total cash of $15 million and total debt of $28.5 million, reflecting an increase due to higher utilization of its credit facility [57] Q&A Session Summary Question: Is there anything preventing the company from pursuing GAC? - Management confirmed there are no barriers to pursuing GAC, emphasizing strong market fundamentals and expected demand [70][71] Question: Any commentary on regulatory undercurrents affecting PAC? - Management stated there is no regulatory uncertainty affecting the PAC business, with existing regulations remaining intact [72] Question: Guidance and free cash flow expectations? - Management indicated that the PAC business is expected to generate free cash flow, with maintenance CapEx anticipated to be lower in the following year [73] Question: Capacity to supply the market if demand increases? - Management confirmed there is capacity to expand PAC production to meet increased demand without cannibalizing GAC production [74] Question: Updates on alternative applications for Corbin wet cake? - Management reported progress in testing asphalt emulsion blending, but significant revenues from this application are not expected in 2026 [92]

Financial Data and Key Metrics Changes - Revenue for the full year 2025 reached approximately $120 million, reflecting a 10% year-over-year increase, driven by solid improvements in average selling price and volumes [51][57] - Adjusted EBITDA for 2025 was $13.2 million, representing a 26% improvement compared to 2024, despite the impact of GAC startup costs [52][56] - Gross margin for the year was 27.9%, negatively impacted by GAC ramp-up costs [51] Business Line Data and Key Metrics Changes - The PAC business delivered exceptional performance in 2025, with revenues reaching approximately $120 million, up 10% year-over-year [38][51] - The company is pausing GAC production to conduct a comprehensive engineering and production process optimization review, with no GAC production expected in 2026 [9][60] - The PAC business is expected to generate adjusted EBITDA of $17 million to $20 million for 2026, based on proven operations [61][58] Market Data and Key Metrics Changes - The GAC market fundamentals remain strong, with persistent supply shortages against steady annual growth from existing demand drivers [27][28] - The company has 96% contract visibility on 2026 targeted volumes and 75% visibility through 2027, indicating strong demand and customer loyalty [44][102] Company Strategy and Development Direction - The company is focused on optimizing its GAC production process and has made strategic changes to its leadership team to enhance operational efficiency [32][36] - The decision to pause GAC production is a disciplined capital allocation decision, not a reflection of lost confidence in the market opportunity [60] - The company aims to transition to purchasing domestic bituminous coal feedstock to eliminate moisture-related production constraints and improve yield [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term demand for GAC, citing a significant demand-supply imbalance that is expected to persist [70][108] - The company is committed to rebuilding investor confidence through consistent execution and delivering on its 2026 PAC guidance [61][62] Other Important Information - The company is taking a $45 million write-down on its Corbin assets as part of its decision to switch GAC feedstock [29][30] - The company ended the year with total cash of $15 million, with total debt of $28.5 million, reflecting increased utilization of its credit facility [56] Q&A Session Summary Question: Is there anything that would prevent the company from pursuing GAC? - Management confirmed there are no barriers to pursuing GAC due to strong market fundamentals and expected demand [69][70] Question: Any commentary on regulatory undercurrents affecting PAC? - Management stated there is no regulatory uncertainty affecting the PAC business, and existing regulations remain intact [72] Question: Guidance for free cash flow and balance sheet considerations? - Management indicated that the PAC business is expected to generate free cash flow, with maintenance CapEx included in the guidance [73] Question: Capacity to supply the market if demand increases? - Management confirmed there is capacity to expand PAC production to meet increased demand without cannibalizing GAC production [74] Question: Updates on alternative applications for Corbin wet cake? - Management provided updates on asphalt emulsion testing and other potential applications, noting progress but cautioning against expecting significant revenues in 2026 [92]

Financial Data and Key Metrics Changes - Q4 revenue reached $48.5 million, a 10.6% increase year-over-year, with an operating loss of $10.6 million resulting in a loss of $0.45 EPS [5][7] - Full year revenue for 2025 was $191.2 million, with over $30 million from new products, marking a 16.2% year-over-year growth, leading to a full year operating loss of $5.9 million and a loss of $0.35 EPS [5][6] - Consolidated gross profit was $12.1 million, up 13.7% from the previous year, with a gross margin of 24.9%, a 70 basis point improvement [9][10] Business Line Data and Key Metrics Changes - Battery and energy product segment revenues were $45.9 million, a 15.1% increase year-over-year, with organic growth driven by a 39.6% increase in medical and a 20.4% increase in industrial and other commercial sectors [7][8] - Communications Systems segment revenues declined to $2.6 million, a 35.2% decrease from the previous year, primarily due to delayed orders [8][9] Market Data and Key Metrics Changes - The sales split for the battery business was 73% commercial and 27% government defense, compared to 70% and 30% respectively in the previous year [8] - The backlog at the end of Q4 was $110.2 million, a 22.1% increase from the previous quarter, representing 58% of trailing twelve months sales [9][10] Company Strategy and Development Direction - The company aims to improve the profitability of its Communications Systems business and enhance gross margins in the battery and energy segment [16][17] - Strategic initiatives include transitioning to a unified brand, consolidating operations, and focusing on vertical integration opportunities following the acquisition of Electrochem [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in 2026, citing a healthy backlog and several new product launches [6][25] - The company is targeting organic growth rates of at least double GDP and aims for EBITDA margins greater than 10% in the short term [27][28] Other Important Information - The company completed its ERP transition and operational initiatives to reduce costs during 2025 [5][6] - The transition of various sub-brands to the Ultralife master brand is expected to streamline operations and reduce costs [19][25] Q&A Session Summary Question: Growth and Margin Expansion Goals - Management indicated a roadmap to achieve organic growth and aims for a minimum of 2x GDP growth, targeting over 10% EBITDA margins in the short term [27] Question: Baseline Revenue for Communications Systems - Baseline revenue for the Communications Systems business is defined as $25 million, with potential for larger orders in the future [29] Question: Medical Order Ramp-Up - A new medical order is expected to generate a six-figure revenue stream annually, with initial product launches beginning soon [30][31]

Financial Data and Key Metrics Changes - In 2025, the company achieved record revenue of $66.6 million, a nearly 20% increase over 2024, with testing volume up over 11% and trailing 12-month ASP up over 7% [21][27][29] - Gross margin for 2025 was just over 58%, down from about 60% in 2024, reflecting ASP pressure experienced in the second half of the year [23][24] - Operating expenses for 2025 were $53 million, up about 13% compared to 2024, indicating early signs of scale in the business as revenue growth outpaced expense growth [24][25] Business Line Data and Key Metrics Changes - The company reset the volume run rate from approximately 30,000 tests in Q1 to over 35,000 tests in subsequent quarters, marking the highest Q4 testing volume in Exagen's history [11][21] - ASP at the end of 2025 was approximately $441, up from $411 at the start of the year, driven by new product enhancements and improved revenue cycle management [12][22] Market Data and Key Metrics Changes - The company expanded its sales force from 40 to 45 territories in 2025, with expectations for improved productivity from new sales representatives over time [12][21] - The Pharma Services segment generated $1.7 million in revenue in 2025, significantly up from roughly $100,000 in 2024, with a backlog value of over $4 million expected to be realized over the next 2-3 years [23] Company Strategy and Development Direction - The company aims to own the entire autoimmune diagnostics space, focusing on comprehensive care and innovation to address significant unmet needs in the market [6][18] - The strategy includes advancing adoption through an upgraded sales force, expanding ASP through revenue cycle optimizations, and driving innovation with a structured product cadence [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve sustainable, profitable growth, with revenue expectations for 2026 set between $70 million to $73 million [18][27] - The company is focused on creating a foundation for innovation and evaluating select inorganic opportunities to support long-term growth [19][20] Other Important Information - The company has five promising assets in development and plans to launch one product each year to expand its addressable market opportunity [15][16] - The American College of Rheumatology has begun advocating for the company's products, which is expected to drive medical policy progress with payers [14][50] Q&A Session Summary Question: Why is it the right time to make investments despite profitability targets? - Management indicated that investments in the commercial organization and R&D are necessary for durable cash flow positivity, emphasizing the importance of achieving sustainable growth [32][35] Question: What is the commercialization target for the myositis product? - The company aims to have the myositis offering ready for the clinic by 2027, with ongoing internal feasibility studies and validation of assays [36][37] Question: What is the expected ASP for Q4 2026? - Management did not disclose specific ASP figures but indicated that they expect stabilization and incremental gains in the second half of 2026 [39][40] Question: How is the Northwell Health situation affecting volume growth? - Management views the Northwell situation as a one-time setback and has seen growth initiatives compensate for any lost volume [40][41] Question: What is the status of the local coverage determination for rheumatologic disease? - The company maintains regular contact with the team at MolDX regarding the draft LCD, which is expected to cover broader testing in rheumatologic conditions [76][77] Question: What are medical directors asking about during discussions? - Medical directors are interested in understanding the clinical impact of the company's tests on patient outcomes and are looking for contemporary data to support their decisions [80][81]

Financial Data and Key Metrics Changes - ZYNLONTA net product revenues in Q4 2025 were $22.3 million, up from $16.4 million in Q4 2024, with full-year revenues at $73.6 million compared to $69.3 million in 2024 [21][22] - Total operating expenses were $41 million for Q4 2025 and $202.9 million for the full year, with adjusted operating expenses down 15% for Q4 and 6% for the full year compared to the previous year [21][22] - The net loss for Q4 2025 was $6.4 million, significantly reduced from a net loss of $30.7 million in Q4 2024, while the full-year net loss was $142.6 million compared to $157.8 million in 2024 [22][23] Business Line Data and Key Metrics Changes - The company focused on ZYNLONTA, optimizing lifecycle management and advancing clinical trials such as LOTIS-5 and LOTIS-7, which are expected to drive future growth [5][6] - The performance in Q4 was strong, driven by variability in customer ordering patterns and activation of new accounts, indicating a positive trend in sales [8] Market Data and Key Metrics Changes - The company anticipates a peak annual U.S. revenue opportunity for ZYNLONTA of $600 million to $1 billion, contingent on regulatory approval and compendia inclusion [7][11] - The treatment landscape for DLBCL is evolving, with a current 60/40 split between complex therapies and broadly accessible therapies, indicating a competitive market environment [15] Company Strategy and Development Direction - The strategic plan focuses on establishing ZYNLONTA as a backbone therapy in DLBCL, with significant patient benefits expected in indolent lymphomas [6][11] - The company aims to maintain a strong market position despite increased competition from bispecific therapies, leveraging its differentiated clinical profile [5][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving key milestones in 2026, including top-line data for LOTIS-5 and further data for LOTIS-7, which are critical for future growth [25][26] - The company believes it has laid a solid foundation for long-term growth, with a strengthened balance sheet and a cash runway extending into 2028 [10][24] Other Important Information - The company has made significant progress in reducing operating costs by approximately 50% while enhancing its leadership and talent across the organization [5][6] - An amendment to the royalty purchase agreement with HealthCare Royalty has provided greater strategic flexibility for the company [10] Q&A Session Summary Question: How are PFS events tracking for LOTIS-5? - Management is confident in the Q2 timing for the top-line readout and will share primary and secondary endpoints at that time [29][30] Question: Is the $200-$300 million opportunity for LOTIS-5 conservative? - Management believes the profile seen in the safety run-in supports a meaningful role in the second-line DLBCL market, with potential for higher peak sales depending on clinical outcomes [34][35] Question: What is the expected R&D spend moving forward? - R&D expenses are expected to decrease in 2026 and 2027, assuming the current number of trials remains stable [42][44] Question: How should capital allocation priorities be viewed? - The company is focused on driving ZYNLONTA growth and has allocated capital for ongoing trials and pre-launch activities, with strategic flexibility provided by the amended royalty agreement [48][50] Question: What is the current commercial run rate for ZYNLONTA? - The company has maintained its market share despite increased competition, with expectations for significant sales growth following LOTIS-5 approval [58][59]

Financial Data and Key Metrics Changes - In Q2 fiscal 2026, the company's sales were nearly $8 billion, reflecting a decline of 2.6% year-over-year, impacted by nearly 500 basis points from optimization actions [14][15] - Adjusted EBITDA grew by 23% to $179 million, with an Adjusted EPS of $0.62, significantly up from $0.22 in the previous year [18][24] - Free cash flow increased by $50 million to $243 million, contributing to a reduction in net debt to its lowest level since fiscal 2018, with a net leverage ratio of 2.7 times [20][21] Business Line Data and Key Metrics Changes - Natural product sales grew by 7%, outperforming the market, while conventional product sales declined by 12%, primarily due to network optimization efforts [15][16] - Retail sales fell by 8%, attributed to strategic store closures, although same-store sales improved sequentially by 100 basis points [16] Market Data and Key Metrics Changes - The company targets a $90 billion addressable market, with expectations for low single-digit average sales growth from fiscal 2026 through fiscal 2028 [11][24] - The overall business outperformed the market, with sales growth in line with the target addressable market's estimated low double- to single-digit growth rate [10][15] Company Strategy and Development Direction - The company is focused on a value creation strategy aimed at achieving profitable growth with customers and suppliers, enhancing capabilities in areas such as supply chain, technology, and private brands [5][12] - The implementation of an AI-powered supply chain planning platform, Relex, is expected to improve customer service and inventory management [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to growth in fiscal 2027, driven by a strong new business pipeline and the cycling of larger optimization actions [10][24] - The company remains focused on helping retailers differentiate themselves in a dynamic market, emphasizing the importance of natural and organic products [11][62] Other Important Information - The company repurchased nearly 750,000 shares for approximately $25 million, reflecting confidence in long-term value creation [22] - An updated outlook for full-year sales is now projected at $31 billion to $31.4 billion, a reduction of 1.9% at the midpoint [23] Q&A Session Summary Question: Impact of network optimization on conventional sales - The company noted a 500 basis point headwind from network optimization, primarily due to the exit from the Allentown facility, which was executed faster than anticipated [30] Question: Underlying business trends in conventional sales - Excluding network optimization impacts, the underlying business showed low single-digit growth, driven by inflation and volume trends [33] Question: Composition of the new business pipeline - The majority of the pipeline consists of incremental categories with existing customers, reflecting healthy relationships and growth opportunities [38] Question: Future of productivity gains - Productivity increased by 6%, driven by automation and lean practices, with expectations for continued improvements [41] Question: Impact of SNAP changes on guidance - The company believes the impact of SNAP changes is manageable and has been factored into the guidance for the remainder of the year [51] Question: Vendor-funded promotions and inflation outlook - Vendor promotions have become more selective, with a focus on peak holiday moments, while inflation is modeled at low single digits for the remainder of the year [67]

Financial Data and Key Metrics Changes - Stagwell reported a 6% growth in 2025, driven by a 13% increase in digital transformation and a 6% increase in marketing services [3] - Adjusted EBITDA for 2025 was $422 million, with a margin of 17.4%, and excluding advocacy, it increased 15.9% to $377 million [9][22] - Free cash flow more than doubled to $187 million, representing nearly 45% conversion of Adjusted EBITDA [25] Business Line Data and Key Metrics Changes - The Marketing Cloud segment exceeded $105 million in revenue, growing 34% organically for the full year, with 41% organic growth in Q4 [6] - Digital transformation and marketing services showed organic growth of 9% and 5% respectively [4] - The marketing cloud grew 230% or 34.3% organically, reflecting increased adoption of its product suite [20] Market Data and Key Metrics Changes - The company expects approximately 10% net revenue growth in 2026, primarily organic, driven by political increases and new business [4] - The media segment is anticipated to return to high single-digit organic growth, supported by new media technology products [8] - The company is entering a political super cycle with over $20 billion expected to be invested in politics [5] Company Strategy and Development Direction - Stagwell is focusing on accelerated organic growth, market share expansion, and advanced AI applications [3] - The company has slowed down planned acquisitions to pivot towards AI application development [5] - A significant buyback program has been announced, reflecting confidence in the company's growth and valuation [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in strong double-digit growth for digital transformation in 2026, driven by increased AI investments [30] - The company anticipates a strong political season, contributing positively to advocacy revenue [36] - Management highlighted the importance of premium creative services, which remain in high demand despite industry disruptions [35] Other Important Information - The company has made significant efficiency gains, with adjusted EBITDA margins improving and a focus on technology-led operational changes [24] - The Marketing Cloud generated a positive margin for the first time in Q4, reaching an Adjusted EBITDA margin of 10.8% [26] - The company has repurchased approximately 55 million shares over the past four years, reflecting a commitment to returning capital to shareholders [27] Q&A Session Summary Question: What is the confidence in the continuation of digital transformation growth? - Management expects even stronger double-digit growth in digital transformation for 2026 due to increased AI investments and a realigned business model [30] Question: What revenue growth and EBITDA contribution are expected from The Machine and Marketing Cloud? - Management anticipates significant interest and potential revenue growth from these products, aiming for at least $25 million in the first year [33] Question: How is creative pacing given AI disruption concerns? - Management noted that premium creative remains in high demand, with agencies achieving record revenues [35] Question: What are the early trends for advocacy in 2026? - Early trends indicate a strong political season ahead, with significant expenditures expected in the upcoming midterm cycle [36] Question: What is the potential for incremental cost-cutting and efficiencies? - Management is on track to achieve $80 million-$100 million in cost actions, with additional potential upside identified [39] Question: What drove the doubling of free cash flow in 2025? - Focus on cash flow management, faster billing, and improved collection processes contributed to the doubling of free cash flow [42]

Financial Data and Key Metrics Changes - The company reported a full-year EBITDA of $111 million, an 11% increase over 2024, with an EBITDA margin of 37% [19] - The fourth quarter EBITDA margin reached a record 42%, marking a significant improvement [5] - The company is projecting 2026 EBITDA guidance of $112 million to $118 million, indicating low double-digit growth over 2025 [5][19] Business Line Data and Key Metrics Changes - The interactive business grew revenue and EBITDA by 53% and 60% respectively in the fourth quarter [4] - The digital business accounted for 51% of EBITDA, with expectations to grow to over 60% by 2026 [19] - The company is focusing on a CapEx-light business model, which is expected to improve cash flow significantly [9] Market Data and Key Metrics Changes - The company is optimistic about expanding its footprint in North America, particularly in Illinois, where it has strong relationships with key customers [12] - iGaming is projected to be more than three times the size of sports betting in states where they compete directly, presenting a significant opportunity [18] Company Strategy and Development Direction - The company is transforming towards a higher growth, higher margin, and less capital-intensive business model [21] - A new cloud-based lottery platform has been launched, with plans to expand its market presence outside the U.S. [63] - The company is combining its gaming and leisure businesses into one reporting entity called Retail Solutions to reflect its current management structure [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth momentum, particularly in the interactive segment, with no signs of slowing down [34][70] - The company is prepared for potential impacts from tax changes in the UK, with strategies in place to mitigate effects [25] - Management remains optimistic about the company's ability to navigate challenges in the operating environment, including geopolitical factors [56] Other Important Information - The company is targeting to reduce net leverage to 2.5-3 times by year-end 2026, which may lead to lower interest rates and better financing options [6] - The company has secured long-term contracts with major customers like bet365 and Entain, ensuring a stable revenue stream [48] Q&A Session Summary Question: Impact of UK tax changes on guidance - Management indicated that customers are adjusting their RTP and bonusing structures to mitigate tax impacts, and they feel comfortable with the expected outcomes [25] Question: Capital allocation strategy amid changing valuations - Management acknowledged the potential for stock repurchase or acquisitions but emphasized a focus on deleveraging at present [28] Question: Expectations for digital business growth - Management confirmed ongoing momentum in the interactive business and highlighted opportunities in new markets like Brazil [34] Question: Retail vs. online marketing strategies - Management noted that operators are looking to balance their marketing strategies between retail and online to mitigate tax impacts [44] Question: Performance of Virtual Sports and Bet Builder product - Management reported modest growth in the Bet Builder product and acknowledged some softening in the Brazil market, but remains optimistic about margin sustainability [50]

Financial Data and Key Metrics Changes - In Q2 fiscal 2026, total sales were nearly $8 billion, a decline of 2.6% year-over-year, impacted by nearly 500 basis points from optimization actions [12][20] - Adjusted EBITDA grew by 23% to $179 million, with an adjusted EPS of $0.62, significantly up from $0.22 in the previous year [16][20] - Free cash flow increased by $50 million to $243 million, contributing to a reduction in net debt to its lowest level since fiscal 2018, with a net leverage ratio of 2.7 times [18][19] Business Line Data and Key Metrics Changes - Natural product sales grew by 7%, outperforming the market, while conventional product sales declined by 12%, primarily due to network optimization [13][14] - Retail sales fell by 8%, largely due to strategic store closures, although same-store sales improved sequentially by 100 basis points [14] Market Data and Key Metrics Changes - The overall business outperformed the market, aligning with the target addressable market's estimated low double- to single-digit growth rate [9][13] - The company is targeting a $90 billion addressable market, focusing on grocers that emphasize differentiation for sustained long-term growth [10] Company Strategy and Development Direction - The company is advancing a value creation strategy aimed at achieving profitable growth with customers and suppliers, focusing on supply chain enhancements, private brands, and technology [4][10] - The implementation of an AI-powered supply chain planning platform, Relex, is expected to improve customer service and inventory management [5][6] Management's Comments on Operating Environment and Future Outlook - Management remains confident in delivering low single-digit average sales growth for fiscal 2026 through fiscal 2028, with expectations for growth returning in fiscal 2027 [10][22] - The company is monitoring the impact of SNAP changes on consumer behavior but believes the effects are manageable and embedded in their outlook [50] Other Important Information - The company repurchased nearly 750,000 shares for approximately $25 million, reflecting confidence in long-term value creation [19] - The updated full-year outlook includes a sales range of $31 billion to $31.4 billion, a reduction from previous expectations, while Adjusted EBITDA and Adjusted EPS expectations have been increased [20][22] Q&A Session Summary Question: Impact of network optimization on conventional sales - The 500 basis points headwind from optimization was more significant than anticipated, primarily due to the exit from the Allentown facility [26][27] Question: Underlying business trends in conventional sales - Excluding optimization impacts, the underlying business showed low single-digit growth, driven by inflation and volume trends [30][31] Question: Pipeline composition for growth - The majority of the pipeline consists of incremental categories with existing customers, reflecting healthy relationships and growth opportunities [35][36] Question: Future of private brand execution - The private brands portfolio is expected to grow faster than the total business, with a focus on innovation and differentiation [94][96] Question: Management of rising diesel costs - The company has tools to manage fuel costs, including hedges and contractual protections, making the situation manageable [92][93]

Financial Data and Key Metrics Changes - Diluted earnings per share reached $3.49, a 50% increase from the prior year [6] - Net income was $130 million, up 49% from the previous year [6] - EBITDA for the quarter was $309 million, reflecting a 27.5% increase year-over-year [6] - Total revenue for the quarter was $3.91 billion, a slight increase of $12 million or 0.3% from the prior year [9] - Gross profit was $1.01 billion, an increase of $94 million or 10.3% from the prior year [10] Business Line Data and Key Metrics Changes - Inside same-store sales increased by 4% for the third quarter, with prepared food and dispensed beverages sales up 4.3% [7] - Grocery and general merchandise sales also rose by 4%, with energy drinks and nicotine alternatives showing double-digit growth [8] - Same-store gallons sold increased by 0.4%, with a fuel margin of $0.41 per gallon [8] Market Data and Key Metrics Changes - The Midcontinent region experienced a 4% decline in fuel gallons sold, indicating market share growth for the company [8] - The average retail price of fuel was $2.72 per gallon, down from $2.85 a year ago [10] Company Strategy and Development Direction - The company is focused on community support through initiatives like the Feeding America campaign [5] - A new culinary initiative involving chicken wings has been expanded to over 550 stores, aiming to complement existing offerings [17] - The company plans to release its next three-year strategic plan at an Investor Day event on June 24 [18] Management's Comments on Operating Environment and Future Outlook - Management noted that volatility in fuel prices is typical and does not significantly impact margins in the long term [21][24] - The company expects fourth-quarter operating expenses to rise in the mid-single digits, influenced by higher variable incentive compensation [16] - Management expressed confidence in the overall health of consumer shopping habits across income cohorts, with growth noted in lower-income segments [36] Other Important Information - The company maintained its quarterly dividend at $0.57 per share and repurchased approximately $76 million in shares during the quarter [14] - The company updated its fiscal 2026 guidance, expecting EBITDA to increase by 18%-20% and inside same-store sales to rise between 3.5%-4.5% [15] Q&A Session Summary Question: Impact of volatility on business - Management acknowledged that volatility is common and typically leads to compressed margins initially, but historically results in net positive margins over time [21][24] Question: Inside same-store sales and pricing impacts - Management indicated that pricing has not been a significant factor in inside sales, with minimal price increases in prepared food [26] Question: Strength in non-alcoholic beverages - Growth in non-alcoholic beverages was primarily driven by energy drinks and flavor-enhanced waters, with no significant stocking behavior noted [32] Question: Customer health across income cohorts - Management reported that all income cohorts are shopping at stores, with lower-income cohorts growing at a slower rate but showing strength in prepared foods [36] Question: Wings rollout and pricing strategy - The rollout of wings will be measured, with pricing aimed to encourage trial and adoption while maintaining a competitive edge [49] Question: Integration of Fikes and future M&A - Management confirmed that integration of Fikes is on track, and the company is positioned to pursue additional acquisitions if opportunities arise [78]